Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Starling Oncology, Inc.
Report date August 16, 2024 · Filed August 20, 2024
Jointly reported with Havencrest Healthcare Partners, L.P., Havencrest Healthcare Partners GP, LLC
Section 16 reporting ended · disclosed 2024-08-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | IndirectSee footnote | 7,884,044 |
Reported balance
After 2024-08-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-08-16 · Other · Disposed 8,701,823 · Balance 7,884,044 F1: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. |
| Common stockSEC Table I · non-derivative | IndirectSee footnote | 252,626 |
Reported balance
After 2024-08-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-08-16 · Other · Disposed 7,631,418 · Balance 252,626 F2: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 16, 2024, TOI HC I, LLC distributed an aggregate of 8,701,823 shares of the Issuer's common stock in a pro-rata in-kind distribution to its members in accordance with the governing documents of TOI HC I, LLC (the "TOI HC 1 Distribution"). Immediately following the TOI HC 1 Distribution, Havencrest Healthcare Partners GP, LLC (the "General Partner") was the record holder of 7,631,418 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.
F2: Also on August 16, 2024, following the TOI HC 1 Distribution, Havencrest Healthcare Partners, L.P. made a further pro-rata in-kind distribution of the 7,631,418 shares it received in the TOI HC 1 Distribution to its limited partners in accordance with the governing documents of Havencrest Healthcare Partners, L.P. (the "Havencrest LP Distribution"). Immediately following the Havencrest LP Distribution, Havencrest Healthcare Partners GP, LLC was the record holder of 152,626 shares of the Issuer's common stock and TOI HC I, LLC was the record holder of 100,000 shares of the Issuer's common stock. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2022 Filed Sep 20, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 68,500 | $4.55 | $311,675.00 |
DisclosureSEC source: 0000899243-22-031553 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 14,933,544 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.90, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 37,785 | $4.99 | $188,547.15 |
DisclosureSEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,002,044 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.86 to $5.30, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 13, 2022 Filed Sep 15, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 52,500 | $5.28 | $277,200.00 |
DisclosureSEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,039,829 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.09 to $5.47, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 12, 2022 Filed Sep 15, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 38,000 | $5.52 | $209,760.00 |
DisclosureSEC source: 0000899243-22-031089 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,092,329 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.12 to $5.88, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 09, 2022 Filed Sep 10, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 18,900 | $5.80 | $109,620.00 |
DisclosureSEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,130,329 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.70 to $5.96, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 08, 2022 Filed Sep 10, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 23,500 | $6.04 | $141,940.00 |
DisclosureSEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,149,229 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.77 to $6.17, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 07, 2022 Filed Sep 10, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 45,000 | $6.04 | $271,800.00 |
DisclosureSEC source: 0000899243-22-030763 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,172,729 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.62 to $6.18, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 84,200 | $5.91 | $497,622.00 |
DisclosureSEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,217,729 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.65 to $6.27, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 02, 2022 Filed Sep 7, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 41,783 | $6.03 | $251,951.49 |
DisclosureSEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,301,929 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.91 to $6.21, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| September 01, 2022 Filed Sep 7, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 31,500 | $6.16 | $194,040.00 |
DisclosureSEC source: 0000899243-22-030551 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,343,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.38, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 25,000 | $6.36 | $159,000.00 |
DisclosureSEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,375,212 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.09 to $6.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 30, 2022 Filed Sep 1, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 38,500 | $6.19 | $238,315.00 |
DisclosureSEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,400,212 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.92 to $6.51, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 29, 2022 Filed Sep 1, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 15,000 | $6.14 | $92,100.00 |
DisclosureSEC source: 0000899243-22-030146 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,438,712 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.91 to $6.32, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 26, 2022 Filed Aug 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 40,000 | $6.03 | $241,200.00 |
DisclosureSEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,453,712 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.85 to $6.27, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 25, 2022 Filed Aug 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 3,525 | $6.20 | $21,855.00 |
DisclosureSEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,493,712 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.40, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 24, 2022 Filed Aug 27, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 21,084 | $6.37 | $134,305.08 |
DisclosureSEC source: 0000899243-22-029900 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,497,237 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.68, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 23, 2022 Filed Aug 24, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 48,100 | $6.54 | $314,574.00 |
DisclosureSEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,518,321 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.35 to $6.69, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 35,500 | $6.53 | $231,815.00 |
DisclosureSEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,566,421 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.31 to $6.66, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 19, 2022 Filed Aug 24, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 10,873 | $6.81 | $74,045.13 |
DisclosureSEC source: 0000899243-22-029569 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,601,921 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.67 to $6.99, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 8,437 | $6.40 | $53,996.80 |
DisclosureSEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 3 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,612,794 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.06 to $6.62, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 16,663 | $6.23 | $103,810.49 |
DisclosureSEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 2 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,621,231 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.50, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
| August 12, 2022 Filed Aug 17, 2022 01:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | SaleCommon stock | 24,900 | $6.69 | $166,581.00 |
DisclosureSEC source: 0000899243-22-028883 · doc4.xml · nonDerivative · entry 1 Havencrest Healthcare Partners, L.P. · CIK 0001705748 · 10% owner Havencrest Healthcare Partners GP, LLC · CIK 0001893722 · 10% owner TOI HC I, LLC · CIK 0001892154 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 15,637,894 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.50 to $7.02, inclusive. The reporting person undertakes to provide The Oncology Institute, Inc., any security holder of The Oncology Institute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. F4 · ownership.nature: TOI HC I, LLC is the record holder of these shares. Havencrest Healthcare Partners, L.P. may be deemed to have beneficial ownership of the shares directly held by TOI HC I, LLC. Havencrest Healthcare Partners GP, LLC controls Havencrest Healthcare Partners, L.P. Each reporting person disclaims beneficial ownership of the reported securities except to the extent of such reporting person's pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.